英派药业-B(07630.HK)与PHARMANOVIA就塞纳帕利于欧洲、中东及北非、澳洲及新西兰签订独家授权协议 有望获得总计最高达4.235亿欧元的交易对价

智通财经
Jul 30
【英派药业-B(07630.HK)与PHARMANOVIA就塞纳帕利于欧洲、中东及北非、澳洲及新西兰签订独家授权协议 有望获得总计最高达4.235亿欧元的交易对价】智通财经APP讯,英派药业-B(07630.HK)公布,集团已与Pharmanovia(一家全球专科制药公司,其与创新生物科技公司及大型制药公司合作,向患者提供创新专科药物)订立独家合作,授予Pharmanovia于欧洲、中东及北非、澳洲及新西兰制造、开发及商业化塞纳帕利的独家权利,用于晚期上皮性高级别卵巢癌、输卵管癌及塬发性腹膜癌的维持单药治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10